Pharmacological properties of faster-acting insulin aspart. Curr. Diabetes Rep. 17, 101 (2017). Article CAS Google Scholar Pieber, T. R., Eugene-Jolchine, I. & Derobert, E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of...
Due to these pharmacological properties, it has been suggested that this type of insulin may have a role in facilitating the transition from continuous intravenous insulin infusion to subcutaneous maintenance therapy in patients with DKA. In one trial the authors hypothesized that the initiation of a...
Heise T, et al. Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial. Diabetes, Obesity & Metabolism 2017; 19(2):208- 215....
2. WANCAI XING, WEI CHEN, YINING ZHANG, JING GAO, ANSHUN HE, JUN ZHANG, YING DENG, FANGKAI XUE, YONGCHUN WANG, HAO FU, RUNYAO ZHANG, JINHUI HUANG, ZHONGRU GAN; 823-P: Molecular and Pharmacological Properties of GZR4, a Once-Weekly Insulin Analog. Diabetes 14 June 2024; 73 (Suppleme...
1.4Pharmacological effects of human insulin and synthetic insulin analogues The aim of optimal insulin therapy indiabetes mellitusis to simulate the control ofglucose metabolismin plasma inendogenous hormonesecretion as naturally as possible. Normal-acting recombinant human insulin is present in the pharmace...
Figure 2 shows results from a study in patients with type 1 diabetes conducted for a maximum of 24 hours after the subcutaneous injection of LEVEMIR. The mean time between injection and the end of pharmacological effect for insulin detemir ranged from 7.6 hours to >24 hours (24 hours was the...
While further studies may permit a more appropriate dose of terbutaline to be selected in future, being able to reduce nocturnal basal insulin infusion for a limited period of time offers a means to reduce nocturnal hypoglycaemia without the need for additional pharmacological therapy. In those ...
The robust effects of GLP-1 RAs to reduce body weight, usually by 2–7 kg (or % of initial body weight) on average in type 2 diabetes, have led to the exploration of GLP-1 RAs as a novel pharmacological treatment in obese but non-diabetic subjects often withimpaired fasting glucoseorgl...
Ghiselli, Giancarlo et al.: “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein,” Cardiovascular Drug Reviews, (1998), vol. 16, No. 1, pp. 16-30. ...
binding as evaluated in vitro would be well tolerated in vivo and be indistinguishable from wild-type insulin with respect to potency or (in the absence of effects on self-assembly) other pharmacological properties—or even more potent and prolonged as in the case of the 2-F-PheB24-DKP-...